Preliminary results of a phase II clinical trial of Genz-112638 in patients with type I Gaucher disease

被引:1
|
作者
Peterschmitt, Judith [1 ,8 ]
Lukina, Elena [2 ,8 ]
Watman, Nora [3 ,8 ]
Banikazemi, Maryam [4 ,8 ]
Iastrebner, Marcelo [5 ,8 ]
Rosenbaum, Hanna [6 ,8 ]
Zimran, Ari [7 ,8 ]
Arreguin, Elsa Avila [7 ,8 ]
O'Brien, Fanny [1 ,8 ]
Smith, Sharon [1 ,8 ]
Puga, Ana Cristina [1 ,8 ]
机构
[1] Genzyme Corp, Cambridge, MA USA
[2] Russian Acad Med Sci, Hematol Res Ctr, Moscow, Russia
[3] Hosp Ramos Mejia, Buenos Aires, DF, Argentina
[4] NYU, New York, NY USA
[5] Inst Argentino Diagnost & Tratamiento, Buenos Aires, DF, Argentina
[6] Rambam Med Ctr, Haifa, Israel
[7] Shaare Zedek Med Ctr, Jerusalem, Israel
[8] Seguro Social Hosp Especialidades, Inst Mexicano, Col La Raza, Mexico
关键词
D O I
10.1016/j.ymgme.2007.10.085
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
73
引用
收藏
页码:S32 / S33
页数:2
相关论文
共 50 条
  • [31] Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: Results of a clinical phase I/II trial
    Yamanaka, R
    Homma, J
    Yajima, N
    Tsuchiya, N
    Sano, M
    Kobayashi, T
    Yoshida, S
    Abe, T
    Narita, M
    Takahashi, M
    Tanaka, R
    CLINICAL CANCER RESEARCH, 2005, 11 (11) : 4160 - 4167
  • [32] Radioimmunotherapy of small volume disease of colorectal cancer:: Results of a clinical phase-I/II trial
    Behr, TM
    Liersch, T
    Canelo, R
    Wörmann, B
    Hiddemann, W
    Ringe, B
    Becker, H
    Becker, W
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S51 - S51
  • [33] TRIHEPTANOIN FOR PATIENTS WITH GLYCOGEN STORAGE DISEASE TYPE I (GSDI): PILOT CLINICAL TRIAL RESULTS
    El-Gharbawy, Areeg
    Cao, Joseph
    Pendyal, Surekha
    Li, Cindy
    Workman, Lauren
    Mavis, Alisha
    Stiles, Ashlee
    Young, Sarah
    MOLECULAR GENETICS AND METABOLISM, 2023, 138 (03) : 46 - 46
  • [34] Phase ii trial of cognitive rehabilitation in patients with multiple sclerosis: preliminary results
    Lopez-Soley, E.
    Solana, E.
    Martinez-Heras, E.
    Munteis, E.
    Ramo, C.
    Presas-Rodriguez, S.
    Hervas, M.
    Romero-Pinel, L.
    Pelayo, R.
    Sanchez-Carrion, R.
    Bernabeu, M.
    Montejo, C.
    Sepulveda, M.
    Sola-Valls, N.
    Blanco, Y.
    Pulido-Valdeolivas, I.
    Andorra, M.
    Alba-Arbalat, S.
    Saiz, A.
    Llufriu, S.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 508 - 509
  • [35] Anti-cachectic effects of a novel peptide nucleic acid: Preliminary results of a phase I/II clinical trial
    D'Olimpio, JT
    Hirschman, SZ
    Shtemer, Z
    Didiego, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 750S - 750S
  • [36] Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: Phase 3 ENGAGE trial final results
    Mistry, Pramod K.
    Lukina, Elena
    Ben Turkia, Hadhami
    Shankar, Suma P.
    Feldman, Hagit Baris
    Ghosn, Marwan
    Mehta, Atul
    Packman, Seymour
    Lau, Heather
    Petakov, Milan
    Assouline, Sarit
    Balwani, Manisha
    Danda, Sumita
    Hadjiev, Evgueniy
    Ortega, Andres
    Foster, Meredith C.
    Gaemers, Sebastiaan J. M.
    Peterschmitt, M. Judith
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (09) : 1156 - 1165
  • [37] A Phase2 clinical trial to assess the safety and tolerability of the pharmacological chaperone AT 2101 in treatment-nave adult patients with type I Gaucher disease
    Mehta, Atul
    Hughes, Derralynn
    Schneider, Eugene
    Dinh, Quinn
    MOLECULAR GENETICS AND METABOLISM, 2010, 99 (02) : S27 - S27
  • [40] Skeletal improvement in patients with Gaucher disease type 1: a phase 2 trial of oral eliglustat
    Kamath, Ravi S.
    Lukina, Elena
    Watman, Nora
    Dragosky, Marta
    Pastores, Gregory M.
    Avila Arreguin, Elsa
    Rosenbaum, Hanna
    Zimran, Ari
    Aguzzi, Rasha
    Puga, Ana Cristina
    Norfleet, Andrea M.
    Peterschmitt, M. Judith
    Rosenthal, Daniel I.
    SKELETAL RADIOLOGY, 2014, 43 (10) : 1353 - 1360